Showcase Your Capabilities to End-To-End Biomarker & Diagnostic-Driven Drug Development Leaders In-Person in 2022
For over a decade, partnering with the 12th Clinical Biomarkers & CDx Summit has been a proven way to attract the attention of precision medicine’s top decision makers.
Witnessing a number of exciting Drug-Dx approvals by the FDA in 2021, for precision & targeted therapy developers the race to market is becoming fiercer in 2022.
As the field continues to rapidly evolve, the need to identify & meet cutting edge service providers is business critical.
Due to the commercial and marketing success this event has historically provided, we’re already running low on partnership opportunities.